



Exact Sciences is a leading global cancer diagnostics company, with more than **6,500 employees worldwide**.



Exact Sciences' workforce is located at **20 sites** worldwide, with headquarters in Madison, Wisconsin. We have additional offices in Wisconsin, California, Arizona, Washington D.C., Utah, Massachusetts, Maryland, France, Italy, United Kingdom, Japan, Germany, and international headquarters in Switzerland.

Exact Sciences' has **10 research & development centers and labs** around the globe in Madison, WI; Marshfield, WI; Redwood City, CA; San Diego, CA; Phoenix, AZ; Baltimore, MD; Cambridge, MA; Oxford, UK; and Munich, Germany. The clinical laboratories are certified under the Clinical Laboratory Improvement Amendments (CLIA) and accredited by the College of American Pathologists (CAP). The lab in Redwood City, CA is an ISO 15189:2012 internationally-recognized accredited laboratory for clinical testing.



In the U.S., Exact Sciences is certified under Fortune's Great Place to Work[®] certified lists. In 2021, 88% of employee survey participants said **Exact Sciences is a Great Place to Work[®]** and 95% are proud to tell others they work for Exact Sciences.¹



Exact Sciences' 2021 revenue was **\$1.77 billion**¹.



Cologuard[®] is the first and only FDA-approved, non-invasive, multi-target, stool DNA-based colorectal cancer screening test. Since it was made available in 2014, Cologuard has helped screen more than **8 million people**¹. For more information, visit www.cologuard.com.



The Oncotype DX[®] portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor to help optimize cancer treatment decisions. With **more than 1.5 million patients tested in more than 90 countries**¹, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.exactsciencespo.com.

Note: tests are available in the United States. Availability outside of the U.S. differs by country.

Cologuard, Oncoguard, and Exact Sciences are registered trademarks of Exact Sciences Corporation. Oncotype, Oncotype DX, Oncomap, and Oncomap EXTra are trademarks of Genomic Health, Inc., a wholly owned subsidiary of Exact Sciences Corporation. All other trademarks are the properties of their respective owners. © 2022 Exact Sciences Corporation. All rights reserved.



The Oncomap[™] test delivers rapid, comprehensive tumor profiling to aid therapy selection for patients with advanced or metastatic, refractory, relapsed, or recurrent cancer, **within 7 days^{1,2} and with patient specimens as small as 3 mm² of tissue, about the size of a grain of rice**¹.



The Oncomap[™] ExTra test detects damage in genes and provides a complete biological picture of certain refractory, rare, or aggressive cancers. **With an extensive exome (DNA) panel of approximately 20,000 genes and 169 introns as well as full transcriptome (RNA) coverage**,³ the Oncomap ExTra test is a comprehensive genomic panel. It provides physicians, academic medical centers, and biopharma researchers with vital interpreted information to help understand changes to a patient's genomic tumor profile and recommend therapeutic treatment plans.



The Oncoguard[®] Liver solution was designed with the hope of bringing better outcomes to more people at risk of Hepatocellular Carcinoma (HCC), the most common form of liver cancer. It includes a **blood test with high performance** designed to enable the detection of early-stage liver cancer. For more information, visit www.oncoguardliver.com.



Exact Sciences is shaping the future of screening by developing a multi-cancer blood test to detect multiple types of cancers at earlier stages through a single blood draw. The company aims to help close the massive screening gap that exists today in which **~70% of incident cancers have no current screening methods**.^{4,5,6} We're also collaborating with Mayo Clinic, Johns Hopkins University, and the Translational Genomics Research Institute (an affiliate of City of Hope) to develop new cancer detection tests, including a solution for minimal residual disease (MRD) testing.



The depth and breadth of the Exact Sciences' pipeline is helping us provide several new cancer solutions to patients through the following innovative cancer diagnostics.

Estimated U.S. Total Addressable Market*

- **\$25B** multi-cancer screening
- **\$18B** colorectal cancer screening
- **\$15B** minimal residual disease & recurrence monitoring

Note: These tests have not been cleared or approved by the FDA and are not available for sale.

*Exact Sciences estimates

1. Internal Data on File. Exact Sciences Corporation, Madison, WI.

2. Turnaround time is based on qualified sample receipt.

3. Science Translational Medicine, 15 Apr 2015; Vol. 7, Issue 283, pp. 283ra53. DOI: 10.1126/sci-translmed.aaa7161

4. Incidence and mortality data from SEER (www.seer.cancer.gov); SEER*Stat Database: Incidence - SEER 18 Regs Research Data, Nov 2018 Sub).

5. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin.* 2022;72(1):7-33.

6. Smith RA, Andrews KS, Brooks D et al. Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. *CA Cancer J Clin* 2019; 69(3):184-210